To interested list members.
            We have recently experienced some very promising results
through an adjunctive protocol which adds S-Adenosyl-Methionine (SAMe)
to our successful MSM/Glucosamine/Chondroitin-based evalutions of the
recent past.   This modification grew from the circumstances surrounding
a small number of advanced osteoarthritis "volunteers" who were unable
to gain complete freedom from pain in and around some of their
articulating joint areas----even after completing the basic protocol.
We were stimulated to investigate SAMe based upon its demonstrated
counteractive effects on cytokines and positive limitations of
homocysteine damage on cartilage.  Through the simple expedient of
adding 400mg to 800mg SAMe daily, to our parent protocol, we were able
to gain, essentially, total pain relief in 3 of these 4 cases.  The
fourth case did enjoy approximately 75% favorable pain resolution (and
well within the tolerable "constant" pain threshold).  This latter case
had suffered massive bone erosion in both knee joints and exhibited very
severe cartilage wasting/damage.   These results were obtained within a
40 day period.  These cases had, previously, exhibited only partial
(50%) response to our basic arthritis protocol and had not achieved
limiting pain to within the "constant" tolerance threshold.
                We believe this information may be of some interest and
import to researchers involved in analyzing the more intractable
arthritis cases.   There were, absolutely, no adverse side-effects
experienced by any of the subjects----all beyond the age of 65 years.
                    I hope this information is of some value to persons
researching this field.
                                                Sincerely.
                                            Brooks Bradley.


--
The silver-list is a moderated forum for discussion of colloidal silver.

To join or quit silver-list or silver-digest send an e-mail message to: 
[email protected]  -or-  [email protected]
with the word subscribe or unsubscribe in the SUBJECT line.

To post, address your message to: [email protected]

List maintainer: Mike Devour <[email protected]>